Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.

Shuhei HaraKeiichiro MoriWataru FukuokayaNaoya TomomasaTakahiro OguchiYusuke TakahashiShun SaitoJun KatamiTakayuki SanoSoushi KadenaMasaki HashimotoYuji YataEriko NishiYushi SuharaShigeyoshi TakamizawaShiro KurawakiHirotaka SuzukiKeiichiro MiyajimaKosuke IwataniFumihiko UrabeKagenori ItoTakafumi YanagisawaShunsuke TsuzukiTatsuya ShimomuraTakahiro Kimura

Published in: International journal of clinical oncology (2024)

In this retrospective study of their efficacy and safety, enzalutamide and apalutamide were shown to exhibit comparable oncological outcomes but quite different AE profiles, suggesting that their differential use may be warranted based on these findings.

Keyphrases

prostate cancer
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
rectal cancer
cross sectional
clinical trial
metabolic syndrome
combination therapy
double blind
glycemic control